Shingles Vaccine Could Lower Heart Disease Risk by 23%, Study Finds

A recent study has found that getting vaccinated against shingles could reduce the risk of cardiovascular events, such as stroke or heart failure, by 23%. The protective benefits of the vaccine, which is primarily used to prevent shingles — a viral infection causing painful rashes — may last for up to eight years, with stronger effects observed in men and individuals under the age of 60.

The study, led by researchers from Kyung Hee University’s College of Medicine in South Korea, analyzed data from over 1.2 million residents aged 50 and above. The research team gathered information on shingles vaccination status from 2012 onward, alongside data on cardiovascular health and lifestyle factors.

Shingles, caused by the same virus responsible for chickenpox, can lead to severe pain and long-term complications, including heart problems. The findings suggest that the vaccine’s effects may extend beyond preventing shingles, potentially offering long-term cardiovascular benefits.

“We observed a significant reduction in the risk of heart-related diseases among those who had received the shingles vaccine,” said the lead researcher. “The results highlight a potential benefit of the vaccine that extends well beyond its primary purpose.”

The study emphasizes the importance of the shingles vaccine as a preventive measure, not just for viral infection but also for overall cardiovascular health. Health experts recommend the vaccine for older adults, as shingles can become more severe with age.

As the research adds a new dimension to the understanding of vaccines and heart disease prevention, further studies are expected to explore the long-term impact of the shingles vaccine on heart health, particularly in different age groups and populations.